References
- Ebbutt A. F. Three-Period Crossover Designs for Two Treatments. Biometrics 1984; 40: 219–224
- Laska E., Meisner M., Kushner H. B. Optimal crossover designs 1n the presence of carryover effects. Biometrics 1983; 39: 1087–1091
- Huitson A., Polonecki J., Hews R., Barker N. A review of crossover trials. The Statistician 1982; 31: 71–80
- Kershner R. P., Federer W. T. Two-treatment crossover designs for estimating a variety of effects. Journal of the American Statistical Association 1981; 76: 612–619
- Fisher A. C., Wallinstein S. Crossover Designs in Medical Research (Chapter 7 of the book: Statistics in the pharmaceutical Industry, C. R. Buncher, J-Y. Tsay. Marcel Dekker, Inc. 1981, Published by).
- Brown B. W., Jr. The crossover experiment for clinical trials. Biometrics 1980; 36: 69–79
- Hills M., Armitage P. The two-period crossover clinical trial. British Journal of Clinical Pharmacology 1979; 8: 7–20
- O'Neill R. T. Subject - Own Control Designs in Clinical Drug Trials: Overview of the Issues with Emphasis on the Two Treatment Problem. Presented at 1978 Annual NcDEU Meeting (May 23–25, 1978. Key Biscayne, Florida 1978
- BEMAC Report. A Report on the Two-Period Crossover Design and its Appliability in Trials of Clinical Effectiveness. 1977
- O'Neill R. T., Cornfield J. Minutes of the June 23. 1976; 1976, meeting of the Biometric and Epidemiological Methodology Advisory Committee, Bureau of Drugs, U.S. Food and Drug Administration.
- McNair D. M. Antianxiety drugs and human performance. Archs. Gen. Psychiat. Chicago 1971; 29: 611–617